ImmuPharma PLC is a pharmaceutical development company listed on AIM of the London Stock Exchange (LSE:IMM). ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. Lupuzor™ is ImmuPharma’s most advanced drug candidate and is a treatment for lupus, a life threatening auto immune disease. Lupuzor ™ has ‘Gold Standard’ approval from the US FDA with a Special Protocol Assessment and “Fast Track” designation. Lupuzor™ has commenced its Phase III pivotal trial. Top line results are expected in Q1 2018. ImmuPharma has a commercially focused Board and management team with extensive industry experience.